Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism
University Hospital, Brest
32 participants
Jun 22, 2023
INTERVENTIONAL
Conditions
Summary
In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases. The "RAMBO" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and/or persistent dyspnea despite anticoagulant therapy. Ventilation/Perfusion (V/Q) PET/CT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V/Q imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology. The EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V/Q PET/CT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V/Q PET/CT imaging.
Eligibility
Inclusion Criteria26
- Patients planned to be randomized
- Abnormal conventional V/Q scan at V1
- Give consent to participate to the EOLE study
- Previsible inability to perform the effort test and/or PR
- Presence of CTEPH according to international guidelines
- Patients treated for acute PE with anticoagulants for more than 8 months
- Active cancer or in remission for less than two years
- Dyspnea post - COVID due to parenchymal injuries
- Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae
- Physical or psychological inability to undertake PR
- Isolated or more distal segmental PE
- Neuro-muscular disease with PR contraindication.
- Cardiac insufficiency (unstable coronary artery disease)
- Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)
- Chronic dyspnea MMRC ≥ 2 before PE
- Cardiac or respiratory rehabilitation in the previous year
- Indication to urgent PR within 6 months at the time of inclusion
- Life expectancy of less than 12 months
- Inability to give consent
- Patient under guardianship or curatorship
- Patient deprived of liberty by an administrative or judicial decision
- Patient has not social security affiliation or who don't beneficiary of such social security
- After initial PR work up, patients with following criteria cannot be included:
- Incapacity to perform the effort test
- Effort test stopped because of hemodynamic intolerance
- Cardiac failure discovered after PR work up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05103670